Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial

Journal of Dermatology

Volumn 41, Issue 7, 2014, Pages 577-585

  Furue, Masutaka ^a   Kitahara, Yasumi ^b   Akama, Hideto ^b   Hojo, Seiichiro ^b   Hayashi, Nobukazu ^c   Nakagawa, Hidemi ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atopic dermatitis; E6005; inflammation; phosphodiesterase 4 inhibitor; topical drug

Indexed keywords

DERMATOLOGICAL AGENT; E6005; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; METHYL 4-(((3-(6,7-DIMETHOXY-2-(METHYLAMINO)QUINAZOLIN-4-YL)PHENYL)AMINO)CARBONYL)BENZOATE; OINTMENT; PHTHALIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA AREA AND SEVERITY INDEX; FEMALE; HUMAN; JAPANESE (PEOPLE); KAPOSI VARICELLIFORM ERUPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEVERITY BEHAVIORAL RATING SCALE; TREATMENT OUTCOME; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; DERMATITIS, ATOPIC; JAPAN; MIDDLE AGED; OINTMENT; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TOPICAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DERMATITIS, ATOPIC; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OINTMENTS; PHOSPHODIESTERASE 4 INHIBITORS; PHTHALIC ACIDS; QUINAZOLINES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903814479     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12534     Document Type: Article

References (30)

1. Akdis CA, Akdis M, Bieber T, et al,. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006; 61: 969-987.
2. Saeki H, Furue M, Furukawa F, et al,. Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563-577.
3. Grewe SR, Chan SC, Hanifin JM,. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 1982; 70: 452-457.
4. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM,. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993; 91: 1179-1188.
5. Hanifin JM, Chan SC, Cheng JB, et al,. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-56.
6. Abrahamsen H, Baillie G, Ngai J, et al,. TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 2004; 173: 4847-4858.
7. Jin SL, Lan L, Zoudilova M, Conti M,. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005; 175: 1523-1531.
8. Yoshida N, Shimizu Y, Kitaichi K, et al,. Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells. Clin Exp Immunol 2001; 126: 384-389.
9. Souness JE, Aldous D, Sargent C,. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 2000; 47: 127-162.
10. Bäumer W, Seegers U, Braun M, Tschernig T, Kietzmann M,. TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Br J Dermatol 2004; 151: 823-830.
11. Pinner NA, Hamilton LA, Hughes A,. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012; 34: 56-66.
12. Nazarian R, Weinberg JM,. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009; 10: 1236-1242.
13. Ishii N, Shirato M, Wakita H, et al,. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther 2013; 346: 105-112.
14. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M,. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11-18.
15. The European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
16. Hosokawa C, Takeuchi S, Furue M,. Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. J Dermatol 2009; 36: 185-190.
17. Reitamo S, Ortonne JP, Sand C, et al,. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-1289.
18. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC,. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330: 516.
19. FK506 ointment research group. A phase 3, randomized study of FK506 in subjects with atopic dermatitis of face and neck. Hifukakiyo 1997; 92: 277-288. (In Japanese.)
20. FK506 ointment research group. A phase 3, randomized study of FK506 in subjects with atopic dermatitis of trunk and limbs. Nishinihonhifuka 1997; 59: 870-879. (In Japanese.)
21. Satoh T, Hosokawa M,. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 1998; 38: 257-288.
22. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC,. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001; 40: 262-269.
23. Robichaud A, Stamatiou PB, Jin SL, et al,. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002; 110: 1045-1052.
24. Qian Y, Girard V, Martin CA, Molimard M, Advenier C,. Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur Respir J 1994; 7: 306-310.
25. Rattenholl A, Steinhoff M,. Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect 2008; 21: 369-381.
26. Lee SE, Jeong SK, Lee SH,. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J 2010; 51: 808-822.
27. Descargues P, Deraison C, Prost C, et al,. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 2006; 126: 1622-1632.
28. Steinhoff M, Neisius U, Ikoma A, et al,. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23: 6176-6180.
29. Akiyama T, Carstens MI, Carstens E,. Enhanced responses of lumbar superficial dorsal horn neurons to intradermal PAR-2 agonist but not histamine in a mouse hindpaw dry skin itch model. J Neurophysiol 2011; 105: 2811-2817.
30. Andoh T, Takayama Y, Yamakoshi T, et al,. Involvement of serine protease and proteinase-activated receptor 2 in dermatophyte-associated itch in mice. J Pharmacol Exp Ther 2012; 343: 91-96.